All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.67 [0.48 ; 0.93 ] CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, Pandit, 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 6 0% 2,148 moderate not evaluable deathsdetailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
Fu, 2020 1.00 [0.02; 51.66]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Pandit, 2021 0.95 [0.02; 50.33]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.65 [0.50 ; 0.85 ] CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, Fu, 2020, Libster, 2020, LIVE-AIR (Temesgen), 2021, Pandit, 2021, SAVE-MORE, 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 10 0% 3,461 moderate low deaths (time to event analysis only)detailed results LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
0.70 [0.40 ; 1.21 ] LIVE-AIR (Temesgen), 2021 1 0% 479 NA not evaluable clinical deteriorationdetailed results COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
Libster, 2020 0.52 [0.29; 0.94]
Ravichandran, 2021 0.02 [0.00; 0.36]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
0.45 [0.26 ; 0.77 ] COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, Libster, 2020, Ravichandran, 2021, SAVE-MORE, 2021 5 57% 587 low not evaluable clinical improvementdetailed results CAN-COVID, 2020 1.39 [0.76; 2.54]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.17 [0.64 ; 2.13 ] CAN-COVID, 2020, Shashi Bhushan, 2021 2 12% 688 moderate not evaluable clinical improvement (14-day)detailed results Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
2.03 [0.17 ; 24.32 ] Pandit, 2021, Shashi Bhushan, 2021 2 75% 281 moderate not evaluable clinical improvement (7-day)detailed results Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.91 [1.03 ; 3.53 ] Shashi Bhushan, 2021 1 0% 222 NA not evaluable death or ventilationdetailed results CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.73 [0.57 ; 0.93 ] CORIMUNO-ANA-1, 2021, LIVE-AIR (Temesgen), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 9% 1,313 moderate not evaluable hospital dischargedetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.48 [1.05 ; 2.09 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
0.35 [0.04 ; 2.76 ] COL-COVID (Pascual-Figal), 2021, SAVE-MORE, 2021 2 0% 697 low not evaluable radiologic improvement (14-day)detailed results Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
2.87 [1.56 ; 5.28 ] Rashad (CLARI vs SoC), 2021 1 0% 198 NA not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Pandit, 2021 2.33 [0.55; 9.83]
Ravichandran, 2021 1.71 [0.80; 3.64]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.60 [0.79 ; 3.24 ] Jagannathan, 2020, Pandit, 2021, Ravichandran, 2021, Shashi Bhushan, 2021 4 75% 523 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance by day 14detailed results Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.18 [0.00 ; 435.69 ] Pandit, 2021, Shashi Bhushan, 2021 2 98% 1,359 moderate not evaluable viral clearance by day 7detailed results Pandit, 2021 2.33 [0.55; 9.83]
Ravichandran, 2021 1.71 [0.80; 3.64]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.26 [1.42 ; 3.61 ] Pandit, 2021, Ravichandran, 2021, Shashi Bhushan, 2021 3 0% 403 moderate not evaluable ICU admissiondetailed results COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
Libster, 2020 0.33 [0.07; 1.58]
0.39 [0.12 ; 1.24 ] COL-COVID (Pascual-Figal), 2021, Libster, 2020 2 0% 263 low not evaluable serious adverse eventsdetailed results CAN-COVID, 2020 0.73 [0.45; 1.19]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
Jagannathan, 2020 1.00 [0.14; 7.34]
Pandit, 2021 0.95 [0.02; 50.33]
0.73 [0.46 ; 1.16 ] CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, Jagannathan, 2020, Pandit, 2021 4 0% 710 moderate not evaluable adverse eventsdetailed results COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
Jagannathan, 2020 1.33 [0.63; 2.78]
Pandit, 2021 1.68 [0.47; 5.97]
Ravichandran, 2021 1.04 [0.02; 52.86]
1.50 [0.90 ; 2.50 ] COL-COVID (Pascual-Figal), 2021, Jagannathan, 2020, Pandit, 2021, Ravichandran, 2021 4 0% 472 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 08:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290